Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Razuprotafib in Hospitalized COVID-19
NCT04511650Phase 2Terminated
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of razuprotafib in coronavirus disease 2019 (COVID-19), sponsored by EyePoint Pharmaceuticals. Started Oct 2020; status: terminated.
02
Drugs
razuprotafib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04511650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511650.